HK1138188A1 - Solid preparation comprising alogliptin and pioglitazone - Google Patents

Solid preparation comprising alogliptin and pioglitazone

Info

Publication number
HK1138188A1
HK1138188A1 HK10103605.9A HK10103605A HK1138188A1 HK 1138188 A1 HK1138188 A1 HK 1138188A1 HK 10103605 A HK10103605 A HK 10103605A HK 1138188 A1 HK1138188 A1 HK 1138188A1
Authority
HK
Hong Kong
Prior art keywords
alogliptin
pioglitazone
solid preparation
preparation
solid
Prior art date
Application number
HK10103605.9A
Other languages
English (en)
Inventor
Kenji Nakamura
Kenichiro Kiyoshima
Junya Nomura
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39240362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1138188(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of HK1138188A1 publication Critical patent/HK1138188A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HK10103605.9A 2007-02-01 2010-04-13 Solid preparation comprising alogliptin and pioglitazone HK1138188A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007023594 2007-02-01
PCT/JP2008/051900 WO2008093882A1 (en) 2007-02-01 2008-01-30 Solid preparation comprising alogliptin and pioglitazone

Publications (1)

Publication Number Publication Date
HK1138188A1 true HK1138188A1 (en) 2010-08-20

Family

ID=39240362

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10103605.9A HK1138188A1 (en) 2007-02-01 2010-04-13 Solid preparation comprising alogliptin and pioglitazone

Country Status (39)

Country Link
US (1) US8637079B2 (me)
EP (1) EP2107905B1 (me)
JP (1) JP5284968B2 (me)
KR (1) KR101486091B1 (me)
CN (1) CN101646420B (me)
AR (1) AR065097A1 (me)
AT (1) ATE488227T1 (me)
AU (1) AU2008211981B2 (me)
BR (1) BRPI0807453B8 (me)
CA (1) CA2677201C (me)
CL (1) CL2008000279A1 (me)
CR (1) CR10992A (me)
CY (1) CY1111264T1 (me)
DE (1) DE602008003522D1 (me)
DK (1) DK2107905T3 (me)
DO (1) DOP2009000195A (me)
EA (1) EA015180B1 (me)
EC (1) ECSP099608A (me)
ES (1) ES2354397T3 (me)
GE (1) GEP20125410B (me)
HK (1) HK1138188A1 (me)
HR (1) HRP20110094T8 (me)
IL (1) IL200108A (me)
JO (1) JO2650B1 (me)
MA (1) MA31169B1 (me)
ME (1) ME01239B (me)
MX (1) MX2009008100A (me)
MY (1) MY147596A (me)
NZ (1) NZ579008A (me)
PE (1) PE20081663A1 (me)
PL (1) PL2107905T3 (me)
PT (1) PT2107905E (me)
RS (1) RS51592B (me)
SI (1) SI2107905T1 (me)
TN (1) TN2009000317A1 (me)
TW (2) TWI453041B (me)
UA (1) UA95828C2 (me)
WO (1) WO2008093882A1 (me)
ZA (1) ZA200905621B (me)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
CN101801351B (zh) * 2007-07-19 2012-12-12 武田药品工业株式会社 包含阿格列汀和盐酸二甲双胍的固体制剂
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
EA031225B1 (ru) 2008-08-15 2018-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы дпп-4 для заживления ран
EP2344195A2 (en) 2008-09-10 2011-07-20 Boehringer Ingelheim International GmbH Combination therapy for the treatment of diabetes and related conditions
UY32126A (es) * 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
JP5685550B2 (ja) 2009-02-13 2015-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sglt2阻害剤、dpp−iv阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
JP2012517977A (ja) 2009-02-13 2012-08-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dpp−4阻害剤(リナグリプチン)を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
NZ602809A (en) * 2010-05-05 2015-02-27 Boehringer Ingelheim Int Pharmaceutical formulations comprising pioglitazone and linagliptin
EA201991014A1 (ru) 2010-06-24 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103877054B (zh) * 2012-12-21 2016-05-25 北大方正集团有限公司 一种苯甲酸阿格列汀片剂及其制备方法
CN103156819A (zh) * 2013-03-29 2013-06-19 山东罗欣药业股份有限公司 苯甲酸阿格列汀组合物片剂及其制备方法
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
JP6027710B1 (ja) * 2014-12-25 2016-11-16 田辺三菱製薬株式会社 糖尿病治療用固形製剤
WO2016202961A1 (en) * 2015-06-17 2016-12-22 H E X A L Aktiengesellschaft Alogliptin formulation
CN108289849A (zh) * 2015-06-26 2018-07-17 韩国联合制药株式会社 莫沙必利与雷贝拉唑的复合制剂
CN105030719B (zh) * 2015-08-20 2018-07-20 杭州成邦医药科技有限公司 一种含有阿格列汀和吡格列酮的组合物
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물
CN113925838B (zh) * 2021-11-11 2022-11-11 乐普制药科技有限公司 一种依帕司他与西格列汀或其可药用盐的复方缓释片及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
DK0559702T3 (da) 1990-11-27 1995-05-15 Byk Gulden Lomberg Chem Fab Urapidil-slow-release-præparat
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6030641A (en) 1997-06-03 2000-02-29 Uni Colloid Kabushiki Kaisha Sustained release capsule and method for preparing the same
JP2931811B2 (ja) 1997-06-03 1999-08-09 ユニコロイド株式会社 徐放性カプセル
WO1998056359A2 (de) 1997-06-13 1998-12-17 Roland Bodmeier Zusammensetzungen, die die wirkstofffreisetzung verzögern
DE19725911A1 (de) 1997-06-13 1998-12-17 Roland Prof Dr Bodmeier Zusammensetzungen, die die Wirkstofffreisetzung verzögern
WO2000016776A1 (fr) 1998-09-18 2000-03-30 Takeda Chemical Industries, Ltd. Preparations a administrer par voie buccale a liberation lente
JP2000154137A (ja) 1998-09-18 2000-06-06 Takeda Chem Ind Ltd 徐放性経口製剤
AU5325200A (en) 1999-06-21 2001-01-09 Eli Lilly And Company Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
JP2003520226A (ja) 2000-01-21 2003-07-02 ノバルティス アクチエンゲゼルシャフト ジペプチジルペプチダーゼ−iv阻害剤および抗糖尿病薬剤を含む組合せ物
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7078397B2 (en) 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
CA2492722A1 (en) 2002-07-11 2004-01-22 Takeda Pharmaceutical Company Limited Production method of coated preparations
IN192749B (me) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
JP4567340B2 (ja) * 2003-01-29 2010-10-20 武田薬品工業株式会社 被覆製剤の製造方法
AU2004208606B2 (en) * 2003-01-29 2009-09-24 Takeda Pharmaceutical Company Limited Process for producing coated preparation
JP4361461B2 (ja) * 2003-10-31 2009-11-11 武田薬品工業株式会社 固形製剤
AU2004285354B2 (en) 2003-10-31 2009-09-17 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
RS57561B1 (sr) 2004-01-20 2018-10-31 Novartis Ag Formulacija dobijena direktnom kompresijom i proces za njeno dobijanje
NZ549716A (en) 2004-03-15 2010-04-30 Takeda Pharmaceutical Pyrimidin-dione derivatives as dipeptidyl peptidase inhibitors
CN101035522B (zh) 2004-10-25 2011-12-07 诺瓦提斯公司 Dpp-ⅳ抑制剂、ppar抗糖尿病剂和二甲双胍的组合
GT200600218A (es) 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
PE20070458A1 (es) 2005-09-14 2007-07-05 Takeda Pharmaceutical Composicion farmaceutica que comprende 2-[[6-(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo como inhibidor de dipeptidil peptidasa
TW200745079A (en) 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
WO2007074884A1 (ja) 2005-12-28 2007-07-05 Takeda Pharmaceutical Company Limited 糖尿病治療剤
PE20110019A1 (es) 2005-12-22 2011-01-27 Takeda Pharmaceutical Composicion farmaceutica que contiene un sensibilizante de insulina y un secretagogo de insulina

Also Published As

Publication number Publication date
WO2008093882A1 (en) 2008-08-07
ATE488227T1 (de) 2010-12-15
PT2107905E (pt) 2010-12-17
JP2010517937A (ja) 2010-05-27
MY147596A (en) 2012-12-31
ME01239B (me) 2013-06-20
TW201350143A (zh) 2013-12-16
BRPI0807453A2 (pt) 2014-05-20
AU2008211981A1 (en) 2008-08-07
IL200108A (en) 2012-02-29
EA200970726A1 (ru) 2010-02-26
EP2107905B1 (en) 2010-11-17
UA95828C2 (ru) 2011-09-12
US8637079B2 (en) 2014-01-28
CY1111264T1 (el) 2015-08-05
US20100092551A1 (en) 2010-04-15
KR20090109115A (ko) 2009-10-19
JP5284968B2 (ja) 2013-09-11
DK2107905T3 (da) 2011-01-31
KR101486091B1 (ko) 2015-01-23
CN101646420A (zh) 2010-02-10
CL2008000279A1 (es) 2008-08-18
SI2107905T1 (sl) 2011-03-31
MX2009008100A (es) 2009-08-07
BRPI0807453B8 (pt) 2021-05-25
RS51592B (en) 2011-08-31
CA2677201C (en) 2015-11-17
JO2650B1 (en) 2012-06-17
GEP20125410B (en) 2012-02-27
HRP20110094T1 (hr) 2011-03-31
BRPI0807453B1 (pt) 2021-01-05
ZA200905621B (en) 2010-10-27
ECSP099608A (es) 2009-09-29
DE602008003522D1 (de) 2010-12-30
HRP20110094T8 (en) 2011-07-31
IL200108A0 (en) 2010-04-15
DOP2009000195A (es) 2009-08-31
PE20081663A1 (es) 2008-12-25
AU2008211981B2 (en) 2012-09-20
AR065097A1 (es) 2009-05-13
TWI453041B (zh) 2014-09-21
CN101646420B (zh) 2012-11-07
EP2107905A1 (en) 2009-10-14
EA015180B1 (ru) 2011-06-30
CA2677201A1 (en) 2008-08-07
MA31169B1 (fr) 2010-02-01
TW200836775A (en) 2008-09-16
CR10992A (es) 2009-09-16
TN2009000317A1 (en) 2010-12-31
ES2354397T3 (es) 2011-03-14
NZ579008A (en) 2012-02-24
PL2107905T3 (pl) 2011-04-29

Similar Documents

Publication Publication Date Title
HK1138188A1 (en) Solid preparation comprising alogliptin and pioglitazone
HK1256805A1 (zh) 藥物組合物和其給藥
ZA201000831B (en) Solid preparation comprising alogliptin and metformin hydrochloride
EP2043647A4 (en) FORMULATION WITH TAXED RELEASE AND CORRESPONDING METHODS
IL205571A0 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin
EP2124550A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND THEIR USE
HK1129566A1 (en) Oral preparation comprising pioglitazone
HK1151791A1 (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
GB0611115D0 (en) Compounds and their use
HK1161720A1 (en) Dihydroetorphines and their preparation
EP2322505A4 (en) 1-ADAMANTYLAZETIDIN-2-ON DERIVATIVE, PREPARATION THEREOF AND PHARMACEUTICAL PREPARATION THEREWITH
GB0714500D0 (en) composition and treatment
EP2348865A4 (en) BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES, THEIR METHODS OF PREPARATION AND THEIR USE
ZA201008384B (en) Lasalocid compositions and methods
GB0821348D0 (en) Compounds and preparation methods
EP2110384A4 (en) HEPATOPOIETIN AND USE THEREOF
GB0813473D0 (en) Antimicrobial preparations and methods
GB0708305D0 (en) Plug and play unit
HU0800405D0 (en) Ewnvironment-friendly biocidis and use thereof
IL207414A0 (en) Siva 3, its preparation and use
GB0610888D0 (en) Compounds and their use
GB0603374D0 (en) Compounds and their use
GB0603376D0 (en) Compounds and their use
GB0603378D0 (en) Compounds and their use
GB0608846D0 (en) Compounds and their use